Cardinal Capital Management Acquires 1,675 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Cardinal Capital Management lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 20.2% during the 1st quarter, Holdings Channel reports. The firm owned 9,955 shares of the biotechnology company’s stock after purchasing an additional 1,675 shares during the period. Cardinal Capital Management’s holdings in United Therapeutics were worth $2,287,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rise Advisors LLC bought a new position in shares of United Therapeutics during the first quarter worth approximately $32,000. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Janiczek Wealth Management LLC boosted its position in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Blue Trust Inc. boosted its position in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 46 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in shares of United Therapeutics by 31.2% during the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 138 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,166.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at $8,530,302.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,166.50. The disclosure for this sale can be found here. Insiders sold 122,744 shares of company stock valued at $31,286,630 over the last quarter. Insiders own 12.50% of the company’s stock.

United Therapeutics Trading Down 0.6 %

Shares of NASDAQ:UTHR traded down $2.02 during mid-day trading on Thursday, reaching $316.93. 458,265 shares of the company’s stock were exchanged, compared to its average volume of 498,540. The firm has a market capitalization of $14.06 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 4.77 and a beta of 0.49. The business’s fifty day moving average price is $271.56 and its 200-day moving average price is $243.07. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $321.80.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same quarter last year, the firm earned $4.86 earnings per share. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. On average, research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company raised their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. Finally, Oppenheimer raised their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.